Carbetocin
Carbetocin is a long-acting oxytocin analog. Carbetocin is a deaminated, carba-substituted oxytocin analog whose modifications resist enzymatic degradation and extend its half-life well beyond that of oxytocin, allowing a single injection where oxytocin needs an infusion. It binds uterine oxytocin receptors to trigger rhythmic myometrial contraction and sustained uterine tone.
For research use only.
Key Facts
- CAS
- 37025-55-1
- Molecular Weight (MW)
- 988.2 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- intravenous, intramuscular
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Long-acting synthetic oxytocin analog used in many countries to prevent uterine atony and postpartum haemorrhage after caesarean delivery. It is not approved by the FDA in the United States.
Peptide Library's Carbetocin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- intravenous, intramuscular
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Carbetocin is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C45H69N11O12S |
|---|---|
| Molecular weight | 988.2 g/mol |
| CAS number | 37025-55-1 |
| PubChem CID | 16681432 |
| FDA UNII | 88TWF8015Y |
| ChEMBL | CHEMBL3301668 |
| DrugBank | DB01282 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Carbetocin is a deaminated, carba-substituted oxytocin analog whose modifications resist enzymatic degradation and extend its half-life well beyond that of oxytocin, allowing a single injection where oxytocin needs an infusion. It binds uterine oxytocin receptors to trigger rhythmic myometrial contraction and sustained uterine tone.
Studies
- Carbetocin vs oxytocin for prevention of postpartum hemorrhage after vaginal delivery: A meta-analysis
- Carbetocin versus oxytocin in the management of the third stage of labor for preventing postpartum hemorrhage after vaginal delivery
- Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis
- The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications
Regulatory & research status
Carbetocin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Carbetocin: frequently asked questions
What is Carbetocin?
Long-acting synthetic oxytocin analog used in many countries to prevent uterine atony and postpartum haemorrhage after caesarean delivery. It is not approved by the FDA in the United States.
How does Carbetocin work?
Carbetocin is a deaminated, carba-substituted oxytocin analog whose modifications resist enzymatic degradation and extend its half-life well beyond that of oxytocin, allowing a single injection where oxytocin needs an infusion. It binds uterine oxytocin receptors to trigger rhythmic myometrial contraction and sustained uterine tone.
Is Carbetocin FDA approved?
No. Carbetocin is not approved by the FDA for any indication and is categorised as prescription-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Carbetocin?
Compounds most often compared with Carbetocin include Oxytocin, Atosiban, ARA 290 (Cibinetide) and Serelaxin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Carbetocin vs oxytocin for prevention of postpartum hemorrhage after vaginal delivery: A meta-analysis — Medicine (Baltimore), 2019External reference
- Carbetocin versus oxytocin in the management of the third stage of labor for preventing postpartum hemorrhage after vaginal delivery — Rev Assoc Med Bras (1992), 2025External reference
- Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial — J Clin Endocrinol Metab, 2023External reference
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis — Cochrane Database Syst Rev, 2025External reference
- The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications — Neurosci Biobehav Rev, 2023External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Carbetocin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Carbetocin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →